ANTIBODY PERSISTENCE 12 MONTHS AFTER A BOOSTER DOSE OF MENINGOCOCCAL-C CONJUGATED VACCINE IN THE SECOND YEAR OF LIFE
- 1 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (8) , 768-770
- https://doi.org/10.1097/inf.0b013e3181d9e653
Abstract
We report on the results of the 12-month follow-up of children aged 14 to 18 months who received primary and booster vaccinations with either a meningococcal-C vaccine conjugated to tetanus toxoid or CRM197. Seroprotection (92.8%) and geometric mean titers/serum bactericidal activity (410.5; 95% CI: 273.4-616.3) were higher in children receiving the meningococcal serogroup C tetanus toxoid conjugate, compared with 61.5% and serum bactericidal antibody geometric mean titer of 45.1 (95% CI: 28.5-71.3) when MenC-CRM197 conjugate was used.Keywords
This publication has 10 references indexed in Scilit:
- A Randomized, Multicenter, Open-Label Clinical Trial to Assess the Immunogenicity of a Meningococcal C Vaccine Booster Dose Administered to Children Aged 14 to 18 MonthsThe Pediatric Infectious Disease Journal, 2010
- Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adultsVaccine, 2009
- Immunogenicity and Reactogenicity of a Booster Dose of a Novel Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine Given to Toddlers of 13–14 Months of Age With Antibody Persistence Up to 31 Months of AgeThe Pediatric Infectious Disease Journal, 2008
- Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational studyBMJ, 2008
- Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccineVaccine, 2006
- Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in SpainVaccine, 2005
- Dynamic Models of Meningococcal Carriage, Disease, and the Impact of Serogroup C Conjugate VaccinationAmerican Journal of Epidemiology, 2005
- Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate VaccineThe Pediatric Infectious Disease Journal, 2005
- Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionThe Lancet, 2004
- Ability of 3 Different Meningococcal C Conjugate Vaccines to Induce Immunologic Memory after a Single Dose in UK ToddlersThe Journal of Infectious Diseases, 2001